Small Molecule Degradation of the microRNA-21 Precursor Rescues Pathogenic Pathways in Cellular Models of Fibrosis
Tenghui WangiD, Xueyi YangiD, Yeongju LeeiD, Jin Hyang SongiD, Jessica L. Childs‐DisneyiD, Joe G. N. GarciaiD, Matthew David DisneyiD
Abstract
MicroRNAs (miRNAs) are short RNA molecules that bind to target mRNAs, resulting in translational repression and gene silencing. Overexpression of microRNA-21 (miR-21) is associated with various human diseases, including autosomal dominant polycystic kidney disease (ADPKD) and pulmonary fibrosis. In this study, a previously described heterobifunctional molecule, TGP-21-RiboTAC, that degrades the miR-21 precursor (pre-miR-21) in triple negative breast cancer cells was investigated in polycystic kidney cell lines and a lung fibroblast cell line. In the former, TGP-21-RiboTAC degraded pre-miR-21 and de-repressed of miR-21s downstream target, Programmed Cell Death 4 (PDCD4) and Peroxisome Proliferator-Activated Receptor alpha (PPAR), known drivers of ADPKD. The heterobifunctional molecule also inhibited cyst growth and rescued the metabolic alterations that occur in ADPKD. In the lung fibroblast cell line, MRC-5, TGP-21-RiboTAC also reduced pre- and mature miR-21 levels, rescued Transforming Growth Factor {beta} (TGF-{beta})-induced repression of SMAD Family Member 7 (SMAD7) and inhibited cell invasion. Collectively, these studies demonstrate the potential of targeted RNA degradation as therapeutic agents that retard the development of organ fibrosis.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 1th percentile
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Drug-like small molecules that inhibit expression of the oncogenic microRNA-21
M. D. Shortridge, B. Chaubey, … G. Varani·bioRxiv·Apr 30, 2022
- MiR-9-5p protects from kidney fibrosis by metabolic reprogramming
Marta Fierro‐Fernández, Verónica Miguel, … Santiago Lamas·The FASEB JournalPeer-reviewed·Nov 22, 2019
- Pirfenidone treatment attenuates fibrosis in autosomal dominant polycystic kidney disease
Viji Remadevi, Abeda Jamadar, … Reena Rao·JCI InsightPeer-reviewed·Sep 21, 2026
- The p21 dependent G2 arrest of the cell cycle in epithelial tubular cells links to the early stage of renal fibrosis
T. Koyano, M. Namba, … M. Matsuyama·bioRxiv·Feb 26, 2019
- Targeting the DNM3OS / miR-199a~214 cluster for the treatment of fibroproliferative diseases
G. Savary, M. Buscot, … N. Pottier·bioRxiv·Jan 4, 2018
- Remdesivir inhibits renal fibrosis in obstructed kidneys